Watts Ryan J.'s Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Oct 22, 2024
- Accession no.
- 0001714899-24-000206
- Filed
- Oct 22, 2024
- Trade date
- Oct 18, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.11M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Watts Ryan J.CIK 0001724310 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 18, 2024 | Common Stock | MOption exerciseAcquired | +40,000 | $0.68 | +$27,200 | 275,807 | Direct | |
| Oct 18, 2024 | Common Stock | SSaleDisposed | −40,000 | $27.69 | −$1,107,600 | 235,807 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 18, 2024 | Common Stock | MOption exerciseDisposed | −40,000 | $0.00 | $0 | 1,078,091 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.